The platform provides equipment such as centrifuges, an ultracentrifuge (Beckman), a chemiluminescence (Chemidoc - Bio-Rad) and fluorescence (Odyssey CLx-LI-COR Biosciences) imager for slides and immunoblots, as well as a plate reader for spectral absorbance, fluorescence and luminescence measurements (SpectraMax i3x - Molecular Devices).
ProteomIC (Proteomics Platform) specialises in advanced protein analysis. It provides research teams with essential equipment to:
- Production of recombinant proteins (FPLC systems (AKTA Pure), lyophilizer, sonicator…).
- Amplification of misfolding proteins (several BMG LABTECH Omega).
- Highly sensitive multiplexed immunodetection (Meso QuickPlex SQ120-MSD, Simoa HD-X).
We also perform sample preparation and fractionation for western blot and dot blot base analyses, and protein extraction for mass spectrometry analyses.
Through a framework contract and collaboration between ESPCI’s SMBC and ICAN’s Omics platforms for metabolomics and lipidomics, researchers will have access to advanced technologies, including:
- MALDI and LC-MS/MS for advanced proteomic analysis.
- Single Cell Proteomics and MS Imaging.
- Analysis of cellular metabolism.
- Quantitative and ultra-sensitive analyses on hundreds of lipid species in various biological matrices.
In the near future, we will make available devices allowing the structural analysis of proteins and their aggregated states via spectrometry, light scattering and calorimetry techniques. In close collaboration with the iGenSeq platform, we will also implement advanced technologies in immunodetection, such as Alamar Biosciences and Olink. In the coming years, efforts will be made to develop collaborations that allow access to structural biology technologies requiring specific expertise, such as cryo-electron microscopy and crystallography.
This platform will study proteins and their interactions, their various isoforms, their aggregated states, and their post-translational modifications (PTM). In particular, it will contribute to research into protein misfolding diseases, such as Alzheimer’s, Parkinson’s and Huntington’s diseases, as well as other neurodegenerative diseases and brain pathologies, including brain tumours, vascular diseases and epilepsy.
Scientific Director: Stéphane HAÏK, MD, PhD, DR1 Inserm
Operational Director: Katarina GRZNAROVA, PhD, Research Engineer